As part of SOSV, one of the worlds most active early stage investors, John Carrigan provides deep expertise and mentorship to support SMEs. In addition, he is heavily involved in recruitment, technical due diligence and program curriculum development for a number of its accelerator programs.

He has also acted as an expert advisor to the European Innovation Council since 2018.

John graduated from University College Dublin in 2005 with a PhD in protein biochemistry. In 2012, he was a founding member of the Aer-Sustainable Energy Limited team, a company that was acquired by Cellulac in 2015. While there, John was responsible for the development of cost-effective natural product extraction (particularly omega oils) from microalgae

Eileen has been working with entrepreneurs since 1990’s where she was part of a consultancy team and small fund. Since 2001 Eileen has worked for Oxford Innovation working on projects relating to business development for SMEs with specific background in business support and Access to Finance and coaching. Since 2004 as Manager of OION Ltd, one of the UKs longest running Angel Networks, overseeing the development of the angel network through to FCA regulation and its own Seed Enterprise Investment Scheme Fund. Her past roles included delivery of National Government programmes including the AngelHub concept and AngelsforLifesciences that now partners with MedCity London. Eileen is a member of the EEN Executive Team for Access to Finance Thematic Group, Board Member of Venturefest Oxford and RSA Fellowship Councillor (Royal Society for the encouragement of Arts, Manufactures and Commerce)

Aleksandra is Medical Director in Roche, leading innovative healthcare company, where she played key roles related to scientific research and market access in different therapeutic areas in Serbia and the region. She specialised programs INSEAD Roche Champions and London Business School 360.

Aleksandra finished School of Medicine in Belgrade with neurology specialisation and worked as a doctor at the Institute of Neurology, Clinical Center of Serbia, before she became part of pharma industry.

Dr Mellad is a scientist entrepreneur passionate about translating innovative technologies into better patient outcomes. As CEO and co-founder of Start Codon, he aims to identify and recruit the most disruptive healthcare start-ups across Europe, seed-fund them and drive their success. Previously, he was the CEO of Cambridge Epigenetix which has developed a proprietary epigenetic biomarker discovery platform for the development of new diagnostic assays and the identification of novel drug targets. While at Cambridge Epigenetix, Jason transformed the research tools company into a leading liquid biopsy player and led two successful fundraisers (Series B and C) for a total of $51m. Prior to joining Cambridge Epigenetix, Jason was a Business Development Manager for Horizon Discovery’s diagnostics division, being responsible for developing and launching new reference standards for genomic clinical assays. Jason obtained his PhD in Medicine from the University of Cambridge with a focus on the molecular mechanisms regulating vascular remodelling within coronary artery bypass grafts.

Laura obtained her PhD in Biotechnology in March 2015. During her PhD, she conducted research in new gene therapy applications in the field of cancer. Laura has worked in technology transfer managing projects in the health sector (diagnostics, pharmaceuticals, medical devices and ICTs) for the past two years. Nowadays, she is an investment analyst at Healthequity SCR and Invivo Ventures FCR, venture capital funds located in Barcelona, investing in SMEs in the Healthcare sector.

An experienced CEO and entrepreneur with a passion for business creativity, out of the box thinking, innovation, technology, and the automotive industry. I enjoy sharing my experiences as a former Oxford start up CEO and board member to inspire other business owners and CEO’s on what is possible if they dare to dream. I have raised over £4 million in venture capital for an Oxford University spin out I founded, from a mix of institutional and angel investors. Prior to moving to the UK I was the founder of a successful software and consulting business in based in Adelaide, South Australia.

Manisha has held many roles in the biotech industry. She attended the University of Pennsylvania for her undergraduate education in Biochemistry and Biology, and received her Ph.D. in Biochemistry from the University of California, San Francisco. She has worked with a wide range of labs and techniques, from cell biology in infectious diseases to crystallography in cancer biology She consulted with several small startups while at UCSF and participated in the Idea to IPO competition, which has spawned many successful startups. She worked in various technical and strategic roles at the Fluidigm and was part of the team that commercialised the world's first single-cell genomics instrument. She now works at Seven Bridges managing the Cancer Genomics Cloud platform.

Prior to his current role, Vincenzo was the Operation Officer and Chief of Staff for Enterprise Data & Analytics Programme, PMO director for Optimising Medical Evidence Generation Activities and Patient Centricity Excellence Director responsible for the strategic direction and delivery leadership of the overall capability programs to enable lifecycle teams to build patient value in R&D.

Following his passion for advancement of medicines for patients, before joining AstraZeneca, Vincenzo has led several projects at GlaxoSmithKline-UK in World Wide Business Development, in the Centres of Excellence for Drug Discovery, in Global Project & Portfolio Management and in Global Medical Affairs.

Vincenzo has contributed to several patented published inventions, successfully led the in-licensing of gene-therapy treatments and built the Global Strategy, Operations and Governance for a number of programmes in Global Medical Affairs, in Global Medicine Development and in BioPharmaceutical R&D within GlaxoSmithKline and AstraZeneca.
Vincenzo is a doctor in medicinal chemistry with an international Project Management accreditation and an MBA in strategic management.

With 9y+ experience in marketing, Rita has been operatively involved in more than 20 startup projects as founder, marketer or freelancer. She is an expert in the field of early-stage growth, performance marketing and strategy focusing on startups. For 3 years, she has been acting as a mentor in 5 acceleration programs across Europe (incl. Techstars Berlin and StartupWiseGuys in the Baltics) and already coached 150+ tech startups (B2B and B2C). Currently she is the Head of Marketing at ZOLLHOF - Tech Incubator, one of the fastest growing startup incubators of Germany and officially the Digital Health Hub founded and backed by the German government. As part of the Digital Health Hub, Rita has been coaching digital health startups over the past couple of years.

Rob Shay has been the Chief Financial Officer for Seven Bridges since June, 2018 and has over 25 years of international financial leadership experience. Rob has served in multiple executive level financial roles for both private and public U.S. companies, partnering with operating leaders to drive long-term growth and improve gross margins through the efficient use of capital and process optimization. Prior to joining Seven Bridges, Rob held leading finance roles at IHSMarkit, supporting both the Energy and Automotive business portfolios. Rob also has M&A and VC fundraising experience having participated in a $1.5B acquisition and Series C raise.Rob received his undergraduate degree in Economics and Government from Bowdoin College and his MBA from the Olin School of Business at Babson College.